Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
MORRISVILLE, N.C., March 03, 2017 -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Monday, Mar. 6, at 8 a.m. Eastern Time to provide an update on the SB204 development program. Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to participate on the call. The phone number to join the conference call is +1 (844) 707-0661 (toll-free in the United States and Canada) or +1 (703) 318-2240 (international). The conference ID for the live call is 77470993. A live webcast will be accessible from the Events page of the Company’s website at http://Events.Novan.com. The webcast will be archived on the Company’s website for 90 days following the live call.
About Novan
Novan, Inc. is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide-releasing platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We are rapidly advancing programs in five dermatological conditions with significant unmet medical need. We believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market.
For more information, visit the Company’s website at www.Novan.com.
CONTACT: (Investors) Sean Andrews, Senior Director of Investor Relations Novan, Inc. 919-627-6847 [email protected] (Media) Deb Holliday Pascale Communications, LLC 412-877-4519 [email protected]
